Peter Ole Jensen

Pharma Equity Group, a listed company on the Nasdaq Copenhagen stock exchange, is fully dedicated to advancing the medical projects of its subsidiary, Reponex Pharmaceuticals A/S. With an unwavering focus on healthcare, Pharma Equity Groups primary objective is to bring significant value to Reponex Pharmaceuticals medical projects. The company is committed to providing extensive support, resources, and expertise to drive the development and success of these projects. As a strategic partner, Pharma Equity Group works closely with Reponex Pharmaceuticals, prioritizing the advancement of innovative medical solutions and breakthrough therapies. Every effort is currently directed towards ensuring the utmost success and impact of Reponex Pharmaceuticals medical projects, with an unwavering dedication to improving global healthcare outcomes. Only when the full potential of Reponex Pharmaceuticals has been unfolded is the intention to explore opportunities to invest in other companies. This approach ensures a strong commitment to the current medical projects and their development, while – on the longer term – remaining open to new strategic investments for continuous growth.

At Avaya, we give our customers the freedom to take their business in the directions that benefit them most. We provide the paths for both customers and their employees where every moment big and small can drive in the moment, memorable experiences. The journey is theirs at the pace that makes sense for them with the innovation without disruption they need now and the solutions they can invest in the future.